Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 27 % of short-term debt in 2026; threshold 65 %.
Financials
Financial year 2026
KML-clinical support from Tessenderlo-Ham, company number BE0472558660, closed financial year 2026 with a result of € -70,352 after tax. For that financial year KML-clinical support recorded a gross margin of € 23,984 and equity of € 1.5 million. Compared with financial year 2025, the result moved from € 245,651 to € -70,352. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 18, 2026.
€ 1.5 million
▼ 4% vs 2025
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -70,352
▼ still € 245,651 profit in 2025
Profit after tax over the fiscal year.
€ 26,808
▲ 124% vs 2025
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 1.5 million.
Debts at end 2026
€ 2 million
▲ 60% vs 2025
€ 181,770 is repaid this year. At this pace the long-term loan is gone in ≈ 11 years.
€ 2,096
▼ 1% vs 2025
Supplier invoices still open on the last day of the fiscal year.
€ 262
▼ 99% vs 2025
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2023 | 2024 | 2025 | 2026 | Change 2025 → 2026 | |
|---|---|---|---|---|---|
| Gross margin | € 51,940 | € 163,976 | € 49,259 | € 23,984 | ▼ 51% |
| Profit after taxes | € -101,158 | € 268,811 | € 245,651 | € -70,352 | ▼ € 316,003 |
| Equity | € 1,095,268 | € 1,364,079 | € 1,609,730 | € 1,539,378 | ▼ 4% |
| Total debts | € 1,511,934 | € 1,481,246 | € 1,512,991 | € 2,270,017 | ▲ 50% |
| Cash | € 16,919 | € 58,191 | € 11,971 | € 26,808 | ▲ 124% |
| Land & buildings | € 2,459,481 | € 2,607,810 | € 2,668,683 | € 3,652,908 | ▲ 37% |
| Retained profit | € 1,076,675 | € 1,345,486 | € 1,591,137 | € 1,520,785 | ▼ 4% |
| Bank debt | € 1,334,677 | € 1,302,908 | € 1,248,571 | € 2,003,469 | ▲ 60% |
| Balance sheet total | € 2,607,202 | € 2,845,324 | € 3,122,720 | € 3,809,395 | ▲ 22% |
Key figures of KML-clinical support, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 31 October 2027.
What happened to KML-clinical support?
What happened at KML-clinical support in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2026: loss of € 70,352 (▼ € 316,003 vs 2025). Source: NBB ↗
- New establishment in Tessenderlo-Ham. KBO
- Start of the company according to the CBE. KBO
In short
From € 101,158 loss in 2023 to € 70,352 loss in 2026.
Paid € 42,513 in corporate taxes since 2023.
Best year ever: 2024, with € 268,811 profit.
Management
Behind KML-clinical support is Kristien Reykers. It owns 100% of Thuisverpleging Reykers itself.
Directors
According to the 2026 annual accounts
Establishments
Establishment units
Physical locations of this company
Laar 67
3980 Tessenderlo-Ham
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0472.558.660
- VAT number
- BE 0472.558.660
- Registered office
- Laar 67, 3980 Tessenderlo-Ham
- Names & denominations
- KML-clinical support
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 8 August 2000
- Peppol
- Active · Active since 24 Nov 2023